Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
J Cell Physiol. 2019 Nov;234(11):19702-19714. doi: 10.1002/jcp.28570. Epub 2019 Apr 5.
Resistance to chemotherapy represents a major cause for treatment failure in multiple myeloma (MM). Herein, this study was conducted to explore the effect of SDF-1/CXCR4 and interleukin-6 (IL-6) in MM cell adhesion-mediated chemoresistance. Enzyme-linked immunosorbent assay was applied to detect expressions of SDF-1α and IL-6 in MM patients and healthy controls. RPMI-8226 cells and isolated bone marrow stromal cells (BMSCs) were stimulated using recombinant SDF-1α and IL-6. Effect of cocultured BMSCs and RPMI-8226 cells on chemosensitivity and apoptosis of RPMI-8226 cells was analyzed. Effect of doxorubicin on the adhesion rate of RPMl-8226 cells to BMSCs was analyzed by calcitonin test. Effect of SDF-1α-induced upregulation of IL-6 on chemotherapeutic resistance and apoptosis of RPMI-8226 cells in adhesion state was analyzed. Cell adhesion model was treated with recombinant protein SDF-1α and phosphoinositide 3-kinase (P13K) inhibitor Wortmarmin. The levels of P13K and protein kinase B (AKT) and its phosphorylation as well as the expression of IL-6 were analyzed. SDF-1α was positively correlated with IL-6. Recombinant human SDF-1α increased IL-6 expression and induced IL-6 secretion in a time- and dose-dependent manner in BMSCs, which was inhibited by IL-6 and SDF-1α neutralizing antibodies. Coculture of MM cells with BMSCs increased the drug resistance and inhibited the apoptosis on MM cells. SDF-1α-induced IL-6 upregulation mediates chemoresistance and apoptosis of RPMI-8226 cells in adhesion state. SDF-1α may up-regulate the expression of IL-6 by activating the P13K/AKT signaling pathway. SDF-1/CXCR4 may up-regulate the expression of IL-6 through the activation of the P13K/AKT signaling pathway, thereby affecting the chemoresistance mediated by adhesion in MM cells.
化疗耐药是多发性骨髓瘤(MM)治疗失败的主要原因。本研究旨在探讨趋化因子 SDF-1/CXCR4 和白细胞介素 6(IL-6)在 MM 细胞黏附介导化疗耐药中的作用。采用酶联免疫吸附试验检测 MM 患者和健康对照者 SDF-1α和 IL-6 的表达。用重组 SDF-1α和 IL-6 刺激 RPMI-8226 细胞和分离的骨髓基质细胞(BMSCs)。分析共培养 BMSCs 和 RPMI-8226 细胞对 RPMI-8226 细胞化疗敏感性和凋亡的影响。通过降钙素试验分析阿霉素对 RPMl-8226 细胞与 BMSCs 黏附率的影响。分析 SDF-1α诱导的 IL-6 上调对黏附状态下 RPMI-8226 细胞化疗耐药和凋亡的影响。用重组蛋白 SDF-1α和磷酸肌醇 3-激酶(PI3K)抑制剂 Wortmarmin 处理细胞黏附模型。分析 PI3K 和蛋白激酶 B(AKT)及其磷酸化水平以及 IL-6 的表达。SDF-1α与 IL-6 呈正相关。重组人 SDF-1α以时间和剂量依赖的方式增加 BMSCs 中 IL-6 的表达并诱导其分泌,IL-6 和 SDF-1α 中和抗体可抑制其作用。MM 细胞与 BMSCs 共培养可增加 MM 细胞的耐药性并抑制其凋亡。SDF-1α诱导的 IL-6 上调介导黏附状态下 RPMI-8226 细胞的化疗耐药和凋亡。SDF-1α可能通过激活 PI3K/AKT 信号通路上调 IL-6 的表达。SDF-1/CXCR4 可能通过激活 PI3K/AKT 信号通路上调 IL-6 的表达,从而影响 MM 细胞黏附介导的化疗耐药。